Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
MAIA Biotechnology, Inc. MAIA

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Apr 16, 2026 8-K 20 signals fired · top 15
Other
Ceo Team Pride Statement Patient Retention High Fast Track Designation Received Interim Data Positive Fast Track Granted Expanded Access Program Active Orphan Status Granted Enrollment Ahead Of Schedule Kol Endorsement
Core
Regulatory Designation Only Clinical Trial Result Combination Therapy Mentioned Lead Asset Progress Indication Expansion
Biotech Risk
Orphan Drug Designation
Apr 8, 2026 8-K 14 signals fired
Core
Regulatory Designation Only Combination Therapy Mentioned Clinical Trial Result Lead Asset Progress Indication Expansion
Other
Fast Track Designation Received Fast Track Granted Orphan Status Granted Interim Data Positive Executive Transition Gratitude Statement Fda Aligned Enrollment Ahead Of Schedule Safety Differentiated
Biotech Risk
Orphan Drug Designation
Mar 31, 2026 8-K 13 signals fired
Other
Interim Data Positive Safety Differentiated Checkpoint Inhibitor Program Expanded Access Program Active Patient Retention High Publication Positive Fast Track Designation Received Enrollment Ahead Of Schedule
Core
Clinical Trial Result Indication Expansion Combination Therapy Mentioned Lead Asset Progress
Biotech Risk
Trial Endpoint Missed
Mar 4, 2026 8-K 18 signals fired · top 15
Other
Fcpa Compliance Representation New York Jurisdiction Clause Corporate Organization And Standing Representation Ipo Net Proceeds Disclosure Use Of Proceeds Disclosure Legal Opinion Methodology Disclosure Form S3 Shelf Registration Disclosure Corporate Authority Representation Legal Opinion Scope Limitation Sanctions Compliance Representation No Regulatory Approval Required Exchange Offer Letter Of Transmittal Registration Rights Piggyback Provision Ipo Or Capital Raising Completion Forward Looking Statement Definition
Feb 24, 2026 8-K 19 signals fired · top 15
Core
Clinical Trial Result Indication Expansion Regulatory Designation Only Combination Therapy Mentioned Lead Asset Progress Clinical Hold
Other
Interim Data Positive Executive Transition Gratitude Statement Kol Endorsement Fast Track Designation Received Enrollment Ahead Of Schedule Safety Differentiated Patient Retention High Fast Track Granted
Biotech Risk
Orphan Drug Designation
Jan 20, 2026 8-K 16 signals fired · top 15
Core
Regulatory Designation Only Indication Expansion Lead Asset Progress Clinical Trial Result Clinical Hold Combination Therapy Mentioned
Other
Interim Data Positive Kol Endorsement Fda Aligned Fast Track Designation Received Enrollment Ahead Of Schedule Orphan Status Granted Fast Track Granted Safety Differentiated
Biotech Risk
Orphan Drug Designation
Dec 17, 2025 8-K 6 signals fired
Other
Ipo Net Proceeds Disclosure Institutional Investment Insider Buying Exchange Offer Letter Of Transmittal Closing Deliverables Specified Warrant Valued Black Scholes
Dec 11, 2025 8-K 22 signals fired · top 15
Other
Enrollment Ahead Of Schedule Insider Buying Interim Data Positive Patient Retention High Fda Aligned Safety Differentiated Fast Track Designation Received Fast Track Granted Expanded Access Program Active
Core
Lead Asset Progress Clinical Trial Result Secondary Endpoint Mentioned Combination Therapy Mentioned Indication Expansion Clinical Hold
Dec 10, 2025 8-K 6 signals fired
Core
Regulatory Designation Only Indication Expansion Lead Asset Progress Combination Therapy Mentioned
Other
Safety Differentiated Interim Data Positive
Nov 21, 2025 8-K 19 signals fired · top 15
Core
Regulatory Designation Only Patient Enrollment Velocity Clinical Trial Result Lead Asset Progress Indication Expansion Combination Therapy Mentioned
Other
Fast Track Designation Received Fast Track Granted Enrollment Ahead Of Schedule Kol Endorsement Orphan Status Granted Expanded Access Program Active Interim Data Positive Safety Differentiated
Biotech Risk
Orphan Drug Designation
Nov 20, 2025 8-K 13 signals fired
Other
Interim Data Positive Kol Endorsement Executive Educational Background Disclosure Safety Differentiated Patient Retention High Expanded Access Program Active Enrollment Ahead Of Schedule Fast Track Designation Received
Core
Clinical Trial Result Regulatory Designation Only Indication Expansion Combination Therapy Mentioned Lead Asset Progress
Nov 7, 2025 10-Q 33 signals fired · top 15
Other
Competition Disclosure Other Income Expense Disclosure Financing Activities Cash Flow Disclosure Cybersecurity Breach Reputational Harm Disclosure Warrant Valued Black Scholes Net Loss Reported Bitcoin Technology Description Liquidity Position Snapshot Disclosed Ipo Or Capital Raising Completion Stock Option Grant Disclosed Institutional Investment Insider Buying Shares Outstanding Disclosure Checkpoint Inhibitor Program
Core
Indication Expansion
Nov 7, 2025 8-K 1 signal fired
Core
Lead Asset Progress
Oct 27, 2025 8-K 12 signals fired
Core
Combination Therapy Mentioned Clinical Trial Result Lead Asset Progress Indication Expansion
Other
Interim Data Positive Enrollment Ahead Of Schedule Expanded Access Program Active Kol Endorsement Safety Differentiated Checkpoint Inhibitor Program Fast Track Designation Received
SaaS
Membership Growing
Oct 24, 2025 8-K 2 signals fired
Core
Lead Asset Progress
Other
Interim Data Positive
Oct 23, 2025 8-K 8 signals fired
Core
Clinical Trial Result Combination Therapy Mentioned Indication Expansion Lead Asset Progress
Other
Interim Data Positive Patient Retention High Publication Positive Checkpoint Inhibitor Program